Spotlight On: Novel Catheter for Treating Peripheral Vascular Disease

SiL Vascular is developing a dual-balloon catheter for the treatment of peripheral vascular disease (a condition that leads to narrowing and hardening of the arteries supplying blood to the legs and feet). The SiL dual-balloon catheter includes a short balloon that moves within a long balloon. This unique dual-balloon configuration overcomes the limitations of standard balloons currently in use.

We interviewed Amichai Baron, the company’s CEO, to find out why doctors, investors, and medical device companies should keep their eyes on SiL Vascular.

trendlines0384

Amichai Baron, CEO of SiL Vascular, presents the company’s technology at the Trendlines 4th Annual Investment Event in Israel in early 2014.

How did the idea for your company develop?

SiL Vascular developed through connections between friends.

Eyal Teichman, a mechanical engineer with vast experience in the medical device field came up with the initial idea behind SiL’s product and co-developed the product with Guy Kotlizky, Ph.D., a patent attorney with fifteen years of experience in developing and patenting medical devices. Guy asked me to establish the company and lead the project based on my extensive management background in medical R&D companies. I contacted my childhood friend (from first grade) David Planer, M.D., who is by chance not only a physician but an expert in peripheral angioplasty. He had just returned to Israel following two years of training at Columbia University in the United States. With this multidisciplinary and experienced team we moved forward to create SiL Vascular in 2013.

 Why do you personally care about your company’s product?

Taking an idea from concept to market is an extremely challenging, exciting, and rewarding task. It is more so when you have a product that solves an unmet medical need and can provide an excellent treatment option to a large population of patients.

Why should others care about the solution you are developing?

Our solution positively impacts long-term quality of life, provides physicians with an improved treatment approach, and reduces costs for healthcare providers and payers.

What advice do you have for a new entrepreneur with a great idea?

Although bringing an idea to market is exciting and rewarding, it can be an extremely frustrating process. It takes a lot of dedication, hard work, and time, especially with medical devices or biotechnology. It’s critical to validate the concept and understand the market, the players, and the regulations.

As you know, Trendlines’ mission is “creating and developing companies that improve the human condition.” How is your company doing this?

Peripheral vascular disease is a common condition with variable morbidity that affects 220 million people worldwide. SiL Vascular’s product is designed to improve short- and long-term clinical outcomes of current procedures and, at the end of the day, lower the risk of amputation. Therefore, it will definitely “improve the human condition.”

Leave a Reply

  • Welcome to Trendlines

    We invest in, incubate, and support early-stage, high-promise medical and agricultural technology companies in Israel, a global leader in start-up ingenuity. Read More >

  • Categories

  • Subscribe to Our Newsletter

  • Stay in Touch

    icon-facebook Like us on Facebook

    icon-Twitter Follow us on Twitter

    icon-Linkedin Connect with us on Linkedin

    YouTube-color See us on YouTube

    flipboard  Read us on Flipboard

    google+_icon Join us on Google+

Font Resize
Contrast